Aflibercept benefits eyes with poor bevacizumab response for vein occlusion-associated macular edema
- Posted on: Jan 15 2019
- Leave a response
Researchers assessed functional and anatomic outcomes in patients who switched therapy for persistent macular edema due to central (CRVO) or hemiretinal vein occlusion (HRVO).
Source: AAO
Posted in: Uncategorized
